Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02,...
MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02,...
SHANGHAI, China, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a...
CHICAGO, IL / ACCESSWIRE / December 1, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
QIAGEN’s ForenSeq Kintelligence System recently used by DNA Labs International in the U.S. to solve unidentified remains case in Oregon...
TORONTO, ON / ACCESSWIRE / November 30, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company) and Celly...
TORONTO, ON / ACCESSWIRE / November 29, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
LANGLEY, BC / ACCESSWIRE / November 29, 2023/ Adastra Holdings Ltd. (CSE:XTRX) (FRA:D2EP) (" Adastra " or the " Company...
Company's DCA Solution Offers Robust Set of User and Medical Practitioner Features via an Android & iOS Mobile App and...
Primary endpoint met Demonstrated safety and reactogenicity of DYAI-100 recombinant proteinC1-cell produced antigen was both safe and well-toleratedNo Serious Adverse...
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),...
Table 1 Change from Baseline Figure 2 Improvements in Clinical Dementia Rating-Sum of Boxes Figure 3 Decrease of Neuroinflammatory Processes...
– CEO and Founder Scott Tarriff Retires – – Chairman Michael Graves to Serve as Interim Executive Chairman – WOODCLIFF...
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Administration...
Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson’s disease Live...
– Teijin to receive exclusive license to further develop and commercialize TransCon™ hGH, TransCon™ PTH, and TransCon™ CNP in Japan...
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary...
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary...
Twenty-seven percent of workers prioritize wellbeing support over salary increase CHICAGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- TELUS Health today...
TORONTO, ON / ACCESSWIRE / November 28, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), is a...
Subsequent Phase Involves Completion of Chemistry, Manufacturing, and Controls (CMC) InformationAinos Intends to Submit Investigational New Drug Applications to the...